Showing 5,021 - 5,040 results of 18,566 for search 'significantly ((((((we decrease) OR (a decrease))) OR (mean decrease))) OR (linear decrease))', query time: 0.44s Refine Results
  1. 5021

    S1 Data - by Jessica C. M. Hui (20370522)

    Published 2024
    “…Compared to the SD, the HFD and SDG models exhibited significantly increased and decreased contraction velocities and could be used as models of diarrhoea and constipation in DM, respectively, while the ED model showed comparatively little change in motility. …”
  2. 5022

    Specifications of prototypes of RSSCA system. by Ngoc-Hai Vu (22290844)

    Published 2025
    “…Compared to conventional PV systems, the RSSCA offers improved light uniformity, better land-use efficiency, and significantly higher electricity generation. However, in regions with limited direct sunlight, such as Seoul in winter, system performance decreases. …”
  3. 5023

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  4. 5024

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  5. 5025

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  6. 5026

    Changes in bioimpedance by sex. by Domingos L. S. Rios (20496173)

    Published 2025
    “…Methods: This study was a retrospective cohort comparing exposure variables in a secondary data analysis with a pre-post treatment design. …”
  7. 5027

    Clinical and epidemiological characteristics. by Domingos L. S. Rios (20496173)

    Published 2025
    “…Methods: This study was a retrospective cohort comparing exposure variables in a secondary data analysis with a pre-post treatment design. …”
  8. 5028

    Changes in bioimpedance by age. by Domingos L. S. Rios (20496173)

    Published 2025
    “…Methods: This study was a retrospective cohort comparing exposure variables in a secondary data analysis with a pre-post treatment design. …”
  9. 5029

    S1 Data - by Domingos L. S. Rios (20496173)

    Published 2025
    “…Methods: This study was a retrospective cohort comparing exposure variables in a secondary data analysis with a pre-post treatment design. …”
  10. 5030
  11. 5031
  12. 5032
  13. 5033
  14. 5034

    Cytochrome bd-II oxidase CyxA promotes the pathogenicity of <i>Klebsiella pneumoniae</i> by resisting oxidative stress by Xiao Xiao (99147)

    Published 2025
    “…Additionally, the expression levels of <i>cyxA</i> at 37°C and 41°C were significantly higher compared to 30°C, and the Δ<i>cyxA</i> strain exhibited significantly lower viable counts, elevated intracellular reactive oxygen species (ROS) levels, and decreased total antioxidant capacity (T-AOC) relative to WT at 37°C and 41°C. …”
  15. 5035
  16. 5036
  17. 5037
  18. 5038
  19. 5039
  20. 5040